MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment - OncoDaily MATTERHORN trial at ASCO 2025: Durvalumab + FLOT improves event-free survival in resectable gastric cancer, signaling a new standard of care.

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment
@ascocancer.bsky.social

oncodaily.com/oncolibrary/...

#ASCO #ASCO2025 #CancerResearch #Duvralumab #GastricCancer #MATTERHORNtrial #OncoDaily #Oncology